Author(s): Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ,
Abstract Share this page
Abstract Neuroendocrine tumors account for approximately 20\% of lung cancers; most (≈15\%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.
This article was published in J Natl Compr Canc Netw
and referenced in Chemotherapy: Open Access